COPD-OSA Overlap Syndrome: Evolving Evidence Regarding Epidemiology, Clinical Consequences, and Management

Chest

Volumn 152, Issue 6, 2017, Pages 1318-1326

  McNicholas, Walter T ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

comorbidity; COPD; epidemiology; management; OSA; overlap syndrome

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; THEOPHYLLINE;

ASTHMA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; DISEASE ASSOCIATION; GASTROINTESTINAL DISEASE; HUMAN; HYPOXIA; INFLAMMATION; NONINVASIVE VENTILATION; OXYGEN DESATURATION; OXYGEN THERAPY; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PRIORITY JOURNAL; REM SLEEP; REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING; SLEEP QUALITY; DISEASE MANAGEMENT; GLOBAL HEALTH; LUNG; LUNG FUNCTION TEST; PATHOPHYSIOLOGY;

COMORBIDITY; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SLEEP APNEA, OBSTRUCTIVE; SLEEP, REM;

EID: 85035009982     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.04.160     Document Type: Review

References (89)

1. Diaz-Guzman, E., Mannino, D.M., Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med 35 (2014), 7–16.
2. Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review [published online ahead of print July 18, 2016]. Sleep Med Rev. http://dx.doi.org/10.1016/j.smrv.2016.07.002.
3. Heinzer, R., Vat, S., Marques-Vidal, P., et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Repir Med 3 (2015), 310–318.
4. Celli, B., Halbert, R., Isonaka, S., et al. Population impact of different definitions of airway obstruction. Eur Respir J 22:2 (2003), 268–273.
5. McSharry, D.G., Ryan, S., Calverley, P., et al. Sleep quality in chronic obstructive pulmonary disease. Respirology 17 (2012), 1119–1124.
6. Valipour, A., Lavie, P., Lothaller, H., et al. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med 12 (2011), 367–372.
7. Agusti, A., Hedner, J., Marin, J.M., et al. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 20 (2011), 183–194.
8. Omachi, T.A., Blanc, P.D., Claman, D.M., et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med 13 (2012), 476–483.
9. Spina G, Spruit MA, Alison J, et al. Analysis of nocturnal actigraphic sleep measures in patients with COPD and their association with daytime physical activity [published online ahead of print January 12, 2017]. Thorax. http://dx.doi.org/10.1136/thoraxjnl-2016-208900.
10. Tsai, S.C., Lee-Chiong, T., Lung hyperinflation and sleep quality in the overlap syndrome. COPD 6 (2009), 419–420.
11. Collop, N., Sleep and sleep disorders in chronic obstructive pulmonary disease. Respiration 80 (2010), 78–86.
12. Lewis, C.A., Fergusson, W., Eaton, T., et al. Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax 64 (2009), 133–138.
13. Johnson, M., Remmers, J., Accessory muscle activity during sleep in chronic obstructive pulmonary disease. J Appl Physiol 57 (1984), 1011–1017.
14. Hudgel, D.W., Devadatta, P., Decrease in functional residual capacity during sleep in normal humans. J Appl Physiol 57 (1984), 1319–1322.
15. McNicholas, W.T., Impact of sleep in COPD. Chest 117 (2000), 48S–53S.
16. McNicholas, W.T., FitzGerald, M.X., Nocturnal death among patients with chronic bronchitis and emphysema. BMJ, 289, 1984, 878.
17. Sanders, M.H., Newman, A.B., Haggerty, C.L., et al. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med 167 (2003), 7–14.
18. Bednarek, M., Plywaczewski, R., Jonczak, L., et al. There is no relationship between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome: a population study. Respiration 72:2 (2005), 142–149.
19. Soler, X., Gaio, E., Powell, F.L., et al. High prevalence of obstructive sleep apnea in patients with moderate to severe chronic obstructive pulmonary disease. Ann Am Thorac Soc 12 (2015), 1219–1225.
20. Steveling, E.H., Clarenbach, C.F., Miedinger, D., et al. Predictors of the overlap syndrome and its association with comorbidities in patients with chronic obstructive pulmonary disease. Respiration 88 (2014), 451–457.
21. Greenberg-Dotan, S., Reuveni, H., Tal, A., et al. Increased prevalence of obstructive lung disease in patients with obstructive sleep apnea. Sleep Breath 18 (2014), 69–75.
22. Ioachimescu, O.C., Teodorescu, M., Integrating the overlap of obstructive lung disease and obstructive sleep apnoea: OLDOSA syndrome. Respirology 18 (2013), 421–431.
23. Zhao, Y.Y., Blackwell, T., Ensrud, K.E., et al. Sleep apnea and obstructive airway disease in older men: outcomes of Sleep Disorders in Older Men Study. Sleep 39 (2016), 1343–1351.
24. Biselli, P., Grossman, P.R., Kirkness, J.P., et al. The effect of increased lung volume in chronic obstructive pulmonary disease on upper airway obstruction during sleep. J Appl Physiol 119 (2015), 266–271.
25. Krachman, S.L., Tiwari, R., Vega, M.E., et al. Effect of emphysema severity on the apnea-hypopnea index in smokers with obstructive sleep apnea. Ann Am Thorac Soc 13 (2016), 1129–1135.
26. White, L.H., Bradley, T.D., Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea. J Physiol 591 (2013), 1179–1193.
27. Renner, B., Mueller, C.A., Shephard, A., Environmental and non-infectious factors in the aetiology of pharyngitis (sore throat). Inflamm Res 61 (2012), 1041–1052.
28. Teodorescu, M., Xie, A., Sorkness, C.A., et al. Effects of inhaled fluticasone on upper airway during sleep and wakefulness in asthma: a pilot study. J Clin Sleep Med 10 (2014), 183–193.
29. Teodorescu, M., Consens, F.B., Bria, W.F., et al. Predictors of habitual snoring and obstructive sleep apnea risk in patients with asthma. Chest 135 (2009), 1125–1132.
30. Wang, Y., Hu, K., Liu, K., et al. Obstructive sleep apnea exacerbates airway inflammation in patients with chronic obstructive pulmonary disease. Sleep Med 16 (2015), 1123–1130.
31. Tuleta, I., Stöckigt, F., Juergens, U.R., et al. Intermittent hypoxia contributes to the lung damage by increased oxidative stress, inflammation, and disbalance in protease/antiprotease system. Lung 194 (2016), 1015–1020.
32. Mulloy, E., McNicholas, W.T., Theophylline in obstructive sleep apnea. A double-blind evaluation. Chest 101 (1992), 753–757.
33. Mulloy, E., McNicholas, W.T., Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 148 (1993), 1030–1036.
34. Kim, V., Han, M.K., Vance, G.B., et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 140 (2011), 626–633.
35. He, B.-T., Lu, G., Xiao, S.-C., et al. Coexistence of OSA may compensate for sleep related reduction in neural respiratory drive in patients with COPD. Thorax 72 (2017), 256–262.
36. Punjabi, N.M., Caffo, B.S., Goodwin, J.L., et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med, 6, 2009, e1000132.
37. Schunemann, H.J., Dorn, J., Grant, B.J.B., et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 118 (2000), 656–664.
38. Putcha, N., Crainiceanu, C., Norato, G., et al. Influence of lung function and sleep-disordered breathing on all-cause mortality. a community-based study. Am J Respir Crit Care Med 194 (2016), 1007–1014.
39. McNicholas, W.T., Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med 180 (2009), 692–700.
40. Mulloy, E., McNicholas, W.T., Ventilation and gas exchange during sleep and exercise in severe COPD. Chest 109 (1996), 387–394.
41. Fletcher, E.C., Luckett, R.A., Miller, T., et al. Pulmonary vascular hemodynamics in chronic lung disease patients with and without oxyhemoglobin desaturation during sleep. Chest 95 (1989), 757–764.
42. Weitzenblum, E., Chaouat, A., Kessler, R., et al. Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 (2008), 237–241.
43. McNicholas, W.T., Chronic obstructive pulmonary disease and obstructive sleep apnoea-the overlap syndrome. J Thorac Dis 8:2 (2016 Feb), 236–242.
44. Chaouat, A., Weitzenbum, E., Krieger, J., et al. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med 151 (1995), 82–86.
45. Agustí A., Noguera, A., Sauleda, J., et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21 (2003), 347–360.
46. Eid, A., Ionescu, A., Nixon, L., et al. Inflammatory Response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001), 1414–1418.
47. Gan, W.Q., Man, S.F.P., Senthilselvan, A., et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 (2004), 574–580.
48. Joppa, P., Petrasova, D., Stancak, B., et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 130 (2006), 326–333.
49. MacNee, W., Oxidants/antioxidants and COPD. Chest 117 (2000), 303S–317S.
50. Wouters, E., Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:1 (2005), 26–33.
51. Vernooy, J.H., Kucukaycan, M., Jacobs, J.A., et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 166 (2002), 1218–1224.
52. Ryan, S., Taylor, C.T., McNicholas, W.T., Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112 (2005), 2660–2667.
53. Ryan, S., Taylor, C.T., McNicholas, W.T., Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 174 (2006), 824–830.
54. Rabinovich, R.A., Figueras, M., Ardite, E., et al. Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. Eur Respir J 21 (2003), 789–794.
55. Takabatake, N., Nakamura, H., Abe, S., et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000), 1179–1184.
56. Broekhuizen, R., Wouters, E., Creutzberg, E., et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61 (2006), 17–22.
57. Dahl, M., Vestbo, J., Lange, P., et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007), 250–255.
58. deTorres, J., Pinto-Plata, V., Casanova, C., et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 133 (2008), 1336–1343.
59. Man, S.F.P., Connett, J.E., Anthonisen, N.R., et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61 (2006), 849–853.
60. Shamsuzzaman, A.S.M., Winnicki, M., Lanfranchi, P., et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105 (2002), 2462–2464.
61. Wu, W.-T., Tsai, S.-S., Shih, T.-S., et al. The impact of obstructive sleep apnea on high-sensitivity C-reactive protein in subjects with or without metabolic syndrome. Sleep Breath 19 (2015), 1449–1457.
62. Ryan, S., Crinion, S.J., McNicholas, W.T., Obesity and sleep-disordered breathing—when two ‘bad guys’ meet. QJM 107 (2014), 949–954.
63. Bradley, T.D., Floras, J.S., Obstructive sleep apnoea and its cardiovascular consequences. Lancet 373 (2009), 82–93.
64. McNicholas, W.T., Bonsignore, M.R., Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29 (2007), 156–178.
65. Fabbri, L.M., Luppi, F., Beghe, B., et al. Complex chronic comorbidities of COPD. Eur Respir J 31 (2008), 204–212.
66. Sin, D.D., Man, S.F.P., Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003), 1514–1519.
67. Somers, V.K., White, D.P., Amin, R., et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing in collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 118 (2008), 1080–1111.
68. Taranto-Montemurro, L., Messineo, L., Perger, E., et al. Cardiac sympathetic hyperactivity in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. COPD 13 (2016), 706–711.
69. Shiina, K., Tomiyama, H., Takata, Y., et al. Overlap syndrome: additive effects of COPD on the cardiovascular damages in patients with OSA. Respir Med 106 (2012), 1335–1341.
70. Nagappa, M., Liao, P., Wong, J., et al. Validation of the STOP-Bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis. PLoS One, 10, 2015, e0143697.
71. Marti-Soler, H., Hirotsu, C., Marques-Vidal, P., et al. The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study. Lancet Respir Med 4 (2016), 742–748.
72. McNicholas, W.T., Screening for sleep-disordered breathing: the continuing search for a reliable predictive questionnaire. Lancet Respir Med 4 (2016), 683–685.
73. Ustun, B., Westover, M.B., Rudin, C., et al. Clinical prediction models for sleep apnea: the importance of medical history over symptoms. J Clin Sleep Med 12 (2016), 161–168.
74. Flemons, W.W., Buysse, D., Redline, S., et al. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 22 (1999), 667–689.
75. Kuna, S.T., Badr, M.S., Kimoff, R.J., et al. An official ATS/AASM/ACCP/ERS workshop report: research priorities in ambulatory management of adults with obstructive sleep apnea. Proc Am Thorac Soc 8 (2011), 1–16.
76. Tkacova, R., McNicholas, W.T., Javorsky, M., et al. Nocturnal intermittent hypoxia predicts prevalent hypertension in the European Sleep Apnoea Database cohort study. Eur Respir J 44 (2014), 931–941.
77. Ryan, S., Doherty, L.S., Rock, C., et al. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease. Respiration 79 (2010), 475–481.
78. McNicholas, W.T., Calverley, P.M.A., Lee, A., et al. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 23 (2004), 825–831.
79. Goldstein, R.S., Ramcharan, V., Bowes, G., et al. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med 310 (1984), 425–429.
80. Lacasse, Y., Bernard, S., Sériès, F., et al. Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial. BMC Pulm Med, 17, 2017, 8.
81. Biselli, P.J.C., Kirkness, J.P., Grote, L., et al. Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study. J Appl Physiol 122 (2017), 82–88.
82. McNicholas, W.T., Coffey, M., Boyle, T., Effects of nasal airflow on breathing during sleep in normal humans. Am Rev Respir Dis 147 (1993), 620–623.
83. McGinley, B.M., Patil, S.P., Kirkness, J.P., et al. A nasal cannula can be used to treat obstructive sleep apnea. Am J Respir Crit Care Med 176 (2007), 194–200.
84. McEvoy, R.D., Pierce, R.J., Hillman, D., et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 64 (2009), 561–566.
85. Struik, F.M., Lacasse, Y., Goldstein, R.S., et al. Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. Respir Med 108 (2014), 329–337.
86. Struik FM, Lacasse Y, Goldstein R, et al. Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease [published online ahead of print June 13, 2013]. Cochrane Database Syst Rev. http://dx.doi.org/10.1002/14651858.CD002878.pub2.
87. Köhnlein, T., Windisch, W., Köhler, D., et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2 (2014), 698–705.
88. Marin, J.M., Soriano, J.B., Carrizo, S.J., et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. Am J Respir Crit Care Med 182 (2010), 325–331.
89. Machado, M.-C.L., Vollmer, W.M., Togeiro, S.M., et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 35 (2010), 132–137.